ILSI-Biomed Israel

Prof. Michael Karin and Prof. Alexander Polyakov – Winners of 2010 Harvey Prize

Prof. Michael Karin and Prof. Alexander Polyakov are the winners of the Technion’s 2010 Harvey Prize. Prof. Karin, from the University of California, San Diego, will receive the prize in the field of human health. He discovered the strong link between obesity, inflammation and cancer. The judges decided to award the prize to Prof. Karin for “his pioneering contribution that led to deciphering the molecular mechanism through which mammalian cells react to cytokines which cause inflammation...

Cancer Biomarkers in the Blood- a research from Technion

Finding the hallmarks of cancer in blood is hard to do — cancer-related proteins are present only in small amounts, are difficult to sort from all of the other circulating proteins, and tend to be eliminated quickly by the body. But one group has devised a method that could turn that around. At the Technion-Israel Institute of Technology in Haifa, Arie Admon and his team have devised a method that combines immunoaffinity purification, microcapillary chromatography, and mass spectrometry to separ...

Meet Rictor, a new molecular target for cancer therapies

The discovery that a protein called Rictor plays a key role in destroying a close cousin of the AKT oncogene could provide scientists with a new molecular target for treating certain cancers, including breast cancer. Described in the September 2010 issue of the journal Molecular Cell, the study was led by scientists at Beth Israel Deaconess Medical Center (BIDMC). The oncogenic cousin, known as SGK1, resembles the widely known AKT oncogene in structure, according to the study's senior...

The new BioInform Magazine – a platform to connect

Two young Israeli scientists - Tal Shprung (M.Sc. in Biochemistry from the faculty of medicine, Tel-Aviv University) and  Alon Rayhman (M.Sc. from the Hebrew University, the faculty of agriculture) have come up with a unique idea for the biotech community in Israel: BioInform - a bio oriented magazine, that is aimed solely to the biotech community in Israel (pharmaceutical companies, medical device industry, biological facilities, academia institutions, ministerial offices and more). ...

May 23-25, 2011: save the date for ILSI-BioMed Israel!

Yes. It is about time to open your calendars and write down the next date: May 23-25 2011. ILSI-BioMed Israel 2011, that is. The 10th international Life Science & Technology Week is just around the corner. Time do flies... The event follows the highly successful 2010 BioMed conference which attracted more than 6000 participants from 51 countries. What an event! ILSI-BioMed 2011 will present high-quality program, featuring top-notch industry executives. Israel's most innovative medi...

Successful Strategies for Medical Device Market Clearance

Getting your product to market as quickly as possible means your company management must navigate its way down the regulatory path wisely and efficiently. Recent changes in the regulatory environment in the U.S. and Europe can make this a challenging and confusing process. Dr. Maria Donawa, Presdient, Roger Gray, Vice President, Quality and Regulatory, and Tami Abudi, Senior Associate, Clinical Affairs, will be presenting this half-day seminar in Israel on October 18 to help your company ...

Aiming for Near-Normal Blood Sugar Did Not Delay Combined Risk of Diabetic Damage for People With Long-standing Diabetes, NIH-Sponsored Trial Finds

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found.  The intensive glucose treatment was compared with standard glucose control. These findings are from the NIH-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.  Although intensive t...

ILSI-BioMed 2010 Has Begun!

This morning the ILSI-BioMed Week 2010 has finally been launched, with 7,000 anticipated participants that will take part in lectures and meetings with the experts and seniors of the bio-pharma and medical equipment industry in Israel and abroad. Following the opening words of the event's organizers, ILSI and Kenes, the president of Israel Shimon Peres came up to the stage and surveyed the future of Israel, which will be based on advanced technologies and serve as an example to the entire...

A French Delegation in the Negev

A French delegation has visited today (Sunday, 13.6.2010) at Ben-Gurion University, as the guest of Bio-Negev, the international center for innovation in the biotechnology industry and life sciences in the Negev. The purpose of the visit is to examine potential collaboration between the visitors and the new initiative in the Negev, BGU being one of the partners in the project. Prof. Rivka Carmi, president of the university, places a great amount of value in the initiative, which can be direct...

Israel’s Life Sciences Export On the Rise

The Coming ILSI–Biomed Israel 2010 Week: The Israel Export and International Cooperation Institute: Life Sciences Export Rose by 14% on the First Quarter of 2010, Summing up to the Total of ca. $1.7 Billion “The first 2010 quarter export of the life sciences industry summed up to ca. $1.7 billion, an increase of about 14 percent compared to the same period last year. This increase is derived from a 15.4 percent increase in the export of medications, which has summed up to ca. $1.3 Billion...